NO20062398L - Daily oral controlled release oxycodone dosage form - Google Patents
Daily oral controlled release oxycodone dosage formInfo
- Publication number
- NO20062398L NO20062398L NO20062398A NO20062398A NO20062398L NO 20062398 L NO20062398 L NO 20062398L NO 20062398 A NO20062398 A NO 20062398A NO 20062398 A NO20062398 A NO 20062398A NO 20062398 L NO20062398 L NO 20062398L
- Authority
- NO
- Norway
- Prior art keywords
- profiles
- dosage form
- controlled release
- daily oral
- oral controlled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Abstract
Det er frembragt oksykodonformuleringer som produserer i det vesentlige flate, in vivo tilstandsstabile plasmaprofiler. Toleransenivåer i samband med slike profiler og toleransenivåer i samband med bifasiske profiler er vist å ikke være statistisk ulike. De i det vesentlige flate, in vivo tilstandsstabile plasmaprofiler blir produsert av doseringsformer med i det vesentlige nulte ordens in vitro frigjøringsprofiler. Slike frigjøringsprofiler produserer for lav enkeltdose in vivo Cmaks-nivåer som kan redusere sannsynligheten for skadelige bivirkninger.Oxycodone formulations have been produced which produce substantially flat, in vivo state-stable plasma profiles. Tolerance levels associated with such profiles and tolerance levels associated with biphasic profiles have been shown to be not statistically different. The substantially flat, in vivo state-stable plasma profiles are produced by dosage forms having substantially zero order in vitro release profiles. Such release profiles produce too low single dose in vivo Cmax levels that can reduce the likelihood of adverse side effects.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51588003P | 2003-10-29 | 2003-10-29 | |
PCT/US2004/036132 WO2005041968A2 (en) | 2003-10-29 | 2004-10-28 | Once-a-day, oral, controlled-release, oxycodone dosage forms |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062398L true NO20062398L (en) | 2006-07-27 |
Family
ID=34549453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062398A NO20062398L (en) | 2003-10-29 | 2006-05-26 | Daily oral controlled release oxycodone dosage form |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1677798A2 (en) |
JP (1) | JP2007509979A (en) |
KR (1) | KR20060108690A (en) |
CN (1) | CN1933837A (en) |
AU (1) | AU2004285547A1 (en) |
BR (1) | BRPI0415639A (en) |
CA (1) | CA2546691A1 (en) |
EC (1) | ECSP066534A (en) |
IL (1) | IL175193A0 (en) |
MA (1) | MA28215A1 (en) |
NO (1) | NO20062398L (en) |
RU (1) | RU2006118323A (en) |
WO (1) | WO2005041968A2 (en) |
ZA (1) | ZA200604310B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1623703B1 (en) | 1999-10-29 | 2011-10-05 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
KR100968128B1 (en) | 2000-10-30 | 2010-07-06 | 유로-셀티크 소시에떼 아노뉨 | Controlled release hydrocodone formulations |
UA81224C2 (en) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Dosage form of oxycodone and use thereof |
US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DE102004032051A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
SA07280459B1 (en) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
DE102007011485A1 (en) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
TWI454288B (en) | 2008-01-25 | 2014-10-01 | Gruenenthal Chemie | Pharmaceutical dosage form |
JP2011511782A (en) | 2008-02-12 | 2011-04-14 | アボット・ラボラトリーズ | Extended release hydrocodone acetaminophen and related methods and uses |
CA2723438C (en) | 2008-05-09 | 2016-10-11 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
ES2534908T3 (en) | 2009-07-22 | 2015-04-30 | Grünenthal GmbH | Hot melt extruded controlled release dosage form |
BR112012001244A2 (en) | 2009-07-22 | 2020-12-08 | Gruünenthal Gmbh | Tamper Resistant DOSAGE FORM, ITS PRODUCTION PROCESS, AND PACKAGING CONTAINING SUCH FORM |
US20110150989A1 (en) * | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
EP2555756B1 (en) * | 2010-04-07 | 2018-08-22 | Lupin Limited | Controlled release pharmaceutical compositions of tapentadol |
MX2013002293A (en) | 2010-09-02 | 2013-05-09 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer. |
JP5925779B2 (en) | 2010-09-02 | 2016-05-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Tamper resistant dosage forms containing inorganic salts |
JP2014524925A (en) | 2011-07-29 | 2014-09-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Tamper-resistant tablets that provide immediate drug release |
JP6063462B2 (en) | 2011-07-29 | 2017-01-18 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Tamper-resistant tablets that provide immediate drug release |
MX356421B (en) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer. |
MX362357B (en) | 2012-04-18 | 2019-01-14 | Gruenenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form. |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
MX2015016254A (en) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Tamper resistant dosage form with bimodal release profile. |
BR112015026549A2 (en) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | tamper-proof dosage form containing one or more particles |
CN105682643B (en) | 2013-07-12 | 2019-12-13 | 格吕伦塔尔有限公司 | Tamper resistant dosage form containing ethylene-vinyl acetate polymer |
CA2931553C (en) | 2013-11-26 | 2022-01-18 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
CA2947786A1 (en) | 2014-05-12 | 2015-11-19 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising tapentadol |
MX2016015417A (en) | 2014-05-26 | 2017-02-22 | Gruenenthal Gmbh | Multiparticles safeguarded against ethanolic dose-dumping. |
CA2983642A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
EP3346991A1 (en) | 2015-09-10 | 2018-07-18 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
IL264593B (en) | 2016-08-10 | 2022-07-01 | Hoffmann La Roche | Pharmaceutical compositions comprising akt protein kinase inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5914131A (en) * | 1994-07-07 | 1999-06-22 | Alza Corporation | Hydromorphone therapy |
UA81224C2 (en) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Dosage form of oxycodone and use thereof |
JP2005525405A (en) * | 2002-04-29 | 2005-08-25 | アルザ・コーポレーシヨン | Method and dosage form for controlling and supplementing oxycodone |
JP2005528423A (en) * | 2002-05-31 | 2005-09-22 | アルザ・コーポレーシヨン | Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone |
-
2004
- 2004-10-28 CN CNA2004800394188A patent/CN1933837A/en active Pending
- 2004-10-28 AU AU2004285547A patent/AU2004285547A1/en not_active Abandoned
- 2004-10-28 WO PCT/US2004/036132 patent/WO2005041968A2/en active Application Filing
- 2004-10-28 RU RU2006118323/15A patent/RU2006118323A/en unknown
- 2004-10-28 KR KR1020067010336A patent/KR20060108690A/en not_active Application Discontinuation
- 2004-10-28 EP EP04817492A patent/EP1677798A2/en not_active Withdrawn
- 2004-10-28 JP JP2006538357A patent/JP2007509979A/en not_active Withdrawn
- 2004-10-28 CA CA002546691A patent/CA2546691A1/en not_active Abandoned
- 2004-10-28 BR BRPI0415639-0A patent/BRPI0415639A/en not_active IP Right Cessation
-
2006
- 2006-04-25 IL IL175193A patent/IL175193A0/en unknown
- 2006-04-28 MA MA28979A patent/MA28215A1/en unknown
- 2006-04-28 EC EC2006006534A patent/ECSP066534A/en unknown
- 2006-05-26 NO NO20062398A patent/NO20062398L/en not_active Application Discontinuation
- 2006-05-26 ZA ZA200604310A patent/ZA200604310B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200604310B (en) | 2007-11-28 |
MA28215A1 (en) | 2006-10-02 |
BRPI0415639A (en) | 2006-12-12 |
EP1677798A2 (en) | 2006-07-12 |
JP2007509979A (en) | 2007-04-19 |
ECSP066534A (en) | 2006-11-24 |
AU2004285547A1 (en) | 2005-05-12 |
CN1933837A (en) | 2007-03-21 |
RU2006118323A (en) | 2007-12-10 |
IL175193A0 (en) | 2008-04-13 |
CA2546691A1 (en) | 2005-05-12 |
WO2005041968A3 (en) | 2006-06-22 |
KR20060108690A (en) | 2006-10-18 |
WO2005041968A2 (en) | 2005-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062398L (en) | Daily oral controlled release oxycodone dosage form | |
TW200718689A (en) | 2-Amino-quinazolin-5-ones | |
CY1112478T1 (en) | KINAZOLINONE COMPOUNDS AS ANTI-CANCER FACTORS | |
GEP20125701B (en) | Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile | |
MXPA05013142A (en) | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents. | |
NO20076613L (en) | Pharmaceutical Formulations and Their Use | |
CA2683786C (en) | Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects | |
SG166093A1 (en) | Inhibitors of brutonæs tyrosine kinase | |
MY147393A (en) | Administration of dipeptidyl peptidase inhibitors | |
EG25822A (en) | Quinolinyl-pyrrolopyrazoles | |
TW200630093A (en) | Dose forms | |
WO2006060507A3 (en) | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders | |
MY143604A (en) | 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidin-5-ones | |
TW200716628A (en) | Novel compounds | |
NZ588913A (en) | Liver cancer drug | |
WO2004006859A3 (en) | Platinum compound | |
TNSN07263A1 (en) | Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them | |
WO2008052139A3 (en) | Ultra low dose doxepin and methods of using the same to treat sleep disorders | |
RU2007122391A (en) | S-MIRTAZAPINE FOR TIDAL TREATMENT | |
EP1503748A4 (en) | Drugs for mitigating taxane-induced neurotoxicity | |
MX2010005009A (en) | Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction. | |
EA200801890A1 (en) | MEANS FOR THE TREATMENT OF NOISE IN THE EARS | |
TW200616951A (en) | Indole derivatives, their manufacture and use as pharmaceutial agents | |
UA93689C2 (en) | Administration of dipeptidyl peptidase inhibitors | |
MY155041A (en) | Methods and dosage forms for reducing side effects of benzisozazole derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |